A Phase 1b/2, single-arm, open-label, multi-center study of MP0250 in combination with osimertinib in patients with EGFR-mutated non-squamous non-small cell lung cancer (NSCLC) pretreated with osimertinib

Administered By

Awarded By

Contributors

Start/End

  • March 27, 2018 - June 9, 2020